Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

F. Ravandi · SciRah

Researcher profile · Semantic Scholar

F. Ravandi

Share profile

F. Ravandi — researcher profile on SciRah

h-index: 127
Works: 2,384
Citations: 68K

Most-cited papers

Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia
C. Dinardo, Wei-Ying Jen, Koichi Takahashi, T. Kadia +34 more
2025Leukemia45 citations
Semantic Scholar
Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab
N. Short, H. Kantarjian, Ken Furudate, Nitin Jain +9 more
2025Journal of Hematology & Oncology31 citations Open access
Semantic Scholar
Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis
Naval G. Daver, J. Senapati, H. Kantarjian, Bo-Fei Wang +22 more
2025Clinical Cancer Research18 citations
Semantic Scholar
Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re-Evaluation of Recommended Dose Adjustments with Azole Antifungals
J. Kawedia, C. Rausch, Xiaoqian Liu, Wei Qiao +13 more
2025American journal of hematology/oncology15 citations Open access
Semantic Scholar
Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements
A. Bataller, Hannah Goulart, G. Issa, C. Dinardo +17 more
2025Leukemia13 citations
Semantic Scholar
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor
N. Short, S. Loghavi, M. Yilmaz, Omer Karrar +16 more
2025Haematologica12 citations Open access
Semantic Scholar
Multi-Modal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification Across Disease States
C. Lachowiez, Georgios Asimomitis, Elsa Bernard, S. Devlin +28 more
2025Blood Cancer Discovery9 citations
Semantic Scholar
Incorporation of Immunotherapy Into Adult B-Cell Acute Lymphoblastic Leukemia Therapy.
F. Haddad, H. Kantarjian, N. Short, Nitin Jain +3 more
2025The Journal of the National Comprehensive Cancer Network9 citations
Semantic Scholar
A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia.
Hannah Goulart, E. Jabbour, N. Short, T. Kadia +5 more
2025Clinical Lymphoma, Myeloma & Leukemia9 citations
Semantic Scholar
Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia.
Roberta S. Azevedo, E. Jabbour, H. Kantarjian, Sravanthi Lavu +7 more
2025Blood6 citations Open access
Semantic Scholar
Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes
A. Bazinet, A. Bataller, K. Chien, Koiji Sasaki +33 more
2026Blood Cancer Journal5 citations Open access
Semantic Scholar
Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML
N. Short, H. Kantarjian, N. Daver, Roberta S. Azevedo +18 more
2026Blood Advances5 citations Open access
Semantic Scholar
A comprehensive analysis of PCR for BCR::ABL1 and next-generation sequencing (NGS)-based measurable residual disease (MRD) with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): Prevalence, association with transcript type, and clinical outcomes
M. Maroun, H. Kantarjian, Nitin Jain, Omer Karrar +12 more
2025Blood5 citations
Semantic Scholar
Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia
Roberta S. Azevedo, E. Jabbour, Nitin Jain, F. Haddad +12 more
2025Blood5 citations
Semantic Scholar
A phase 2 trial of CPX-351 combined with venetoclax in relapsed or refractory acute myeloid leukemia
T. Kadia, Wei-Ying Jen, A. Bataller, A. Bazinet +17 more
2025American journal of hematology/oncology5 citations
Semantic Scholar
Integrated analysis of genomics, molecular responses and outcomes of CBF-AML with FLAG based therapy on a phase 2 trial
J. Senapati, H. Kantarjian, Edward Ayoub, Andrés E. Quesada +17 more
2026Blood Cancer Discovery4 citations Open access
Semantic Scholar
Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.
C. Zent, E. Tiacci, Robert J. Kreitman, Tamar Tadmor +43 more
2026Blood4 citations Open access
Semantic Scholar
The Care and Cure of the Leukemias in 2026
H. Kantarjian, H. Chifotides, F. Haddad, E. Jabbour +6 more
2026American journal of hematology/oncology4 citations
Semantic Scholar
The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study
Hannah Goulart, H. Kantarjian, Nitin Jain, Rita Khouri +13 more
2025Blood4 citations
Semantic Scholar
Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy
A. Bazinet, S. Loghavi, Yue-Huan Wei, A. Bataller +26 more
2025Leukemia4 citations
Semantic Scholar
Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis
Hannah Goulart, H. Kantarjian, K. Sasaki, Nitin Jain +15 more
2025Blood4 citations
Semantic Scholar
Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell/myeloid mixed phenotype acute leukemia
Roberta S. Azevedo, Wei-Ying Jen, D. Hammond, Fadi G. Haddad +8 more
2025Haematologica4 citations Open access
Semantic Scholar
CD123 expression and its correlation with mutation profile in acute myeloid leukaemia
Roberta S. Azevedo, Sa A. Wang, D. Swanson, Naval G. Daver +17 more
2025British Journal of Haematology4 citations
Semantic Scholar
Tyrosine Kinase Inhibitors During Frontline Therapy in Adults With Acute Lymphoblastic Leukemia With ABL-class Rearrangements.
J. Braish, H. Kantarjian, N. Short, Gui-Lin Tang +10 more
2025Clinical Lymphoma, Myeloma & Leukemia4 citations
Semantic Scholar
Prospective feasibility study of peripheral blood for MRD detection in acute myeloid leukemia by flow cytometry
Shao-Ying Li, N. Short, Wei Wang, J. Ling +10 more
2026Blood Advances3 citations Open access
Semantic Scholar
Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.
Thura Win Htut, Jeannot Kekedjian, N. Short, A. Bazinet +21 more
2026Haematologica3 citations Open access
Semantic Scholar
Immunophenotypic changes following menin inhibition in acute myeloid leukemia
S. Loghavi, Aziz Farhat, Trevor Jamison, Georgina El Hajjar +21 more
2026Leukemia3 citations Open access
Semantic Scholar
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.
D. Pollyea, Jessica K. Altman, R. Assi, K. Bachiashvili +35 more
2026The Journal of the National Comprehensive Cancer Network3 citations
Semantic Scholar
Outcome of second‐line therapy in adult B‐cell acute lymphoblastic leukemia
H. Kantarjian, Wei Qiao, Nitin Jain, Wei-Ying Jen +10 more
2026Cancer3 citations
Semantic Scholar
Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome
Roberta S. Azevedo, N. Short, A. Bataller, N. Daver +16 more
2025Blood3 citations
Semantic Scholar
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia
G. Montalban-Bravo, S. Loghavi, Ziyi Li, K. Chien +28 more
2025Blood Advances3 citations
Semantic Scholar
Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B-cell acute lymphoblastic leukemia: Long-term follow-up from a phase 2 Study
Hannah Goulart, E. Jabbour, Nitin Jain, T. Kadia +12 more
2025Blood3 citations
Semantic Scholar
Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
T. Kadia, A. Bataller, A. Bazinet, G. Borthakur +26 more
2026American journal of hematology/oncology2 citations
Semantic Scholar
Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AML
Jennifer Marvin-Peek, H. Kantarjian, Wei-Ying Jen, Naval G. Daver +16 more
2026American journal of hematology/oncology2 citations
Semantic Scholar
Impact of high-sensitivity next-generation sequencing, measurable residual disease and subsequent stem cell transplant in patients receiving blinatumomab for MRD-positive B-cell acute lymphoblastic leukemia.
Daniel Nguyen, E. Jabbour, H. Kantarjian, W. Macaron +11 more
2026Haematologica2 citations Open access
Semantic Scholar
The role of advanced molecular diagnostics in informing targeted therapies for AML.
Jennifer Marvin-Peek, S. Loghavi, G. Issa, N. Daver +3 more
2026Human Pathology2 citations
Semantic Scholar
Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia
Darren Lee, Yazan Abu-Shihab, Kate Plas, D. Nicolet +28 more
2026Leukemia2 citations Open access
Semantic Scholar
Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).
G. Issa, Branko Cuglievan, Georgina El Hajjar, Wei-Ying Jen +28 more
2026Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Incorporation of genomic determinants improves diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia.
G. Montalban-Bravo, Chong Wu, J. J. Rodríguez-Sevilla, Yue Wei +37 more
2026Blood Cancer Discovery2 citations
Semantic Scholar
Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy.
Sven Turkalj, F. A. Radtke, B. Stoilova, R. Mecklenbrauck +20 more
2025Blood2 citations Open access
Semantic Scholar
A Phase 2 study of CPX‐351 in combination with venetoclax in patients with newly diagnosed high‐risk acute myeloid leukemia
Wei-Ying Jen, J. Croden, Emmanuel Almanza-Huante, C. Dinardo +15 more
2025HemaSphere2 citations Open access
Semantic Scholar
AML-150: A Phase 1b/2 Trial of an All-Oral “Triplet” Regimen for IDH-Mutated Myeloid Malignancies: Decitabine or Cedazuridine and Venetoclax in Combination with Ivosidenib or Enasidenib
Jennifer Marvin-Peek, A. Maiti, Y. Alvarado, N. Daver +27 more
2025Clinical Lymphoma, Myeloma & Leukemia2 citations
Semantic Scholar
A case series of oral decitabine–cedazuridine with venetoclax for blastic plasmacytoid dendritic cell neoplasm
Hannah Goulart, G. Garcia-Manero, T. Kadia, N. Daver +7 more
2025Leukemia and Lymphoma2 citations
Semantic Scholar
Blinatumomab and Ponatinib Versus Hyper‐CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis
Koiji Sasaki, H. Kantarjian, C. Rausch, Hannah Goulart +14 more
2026American journal of hematology/oncology1 citations
Semantic Scholar
Outcomes of therapy‐related non‐core binding factor acute myeloid leukemia with venetoclax‐based therapies
J. Senapati, J. Croden, G. Garcia-Manero, Koichi Takahashi +18 more
2026HemaSphere1 citations Open access
Semantic Scholar
Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia
Aziz Farhat, Georgina El Hajjar, H. Kantarjian, Koiji Sasaki +18 more
2026Cancer1 citations Open access
Semantic Scholar
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia
Elias J. Jabbour, C. Rausch, Hannah Goulart, Nitin Jain +14 more
2026Blood Cancer Journal1 citations Open access
Semantic Scholar
Performance of molecular scoring systems in hypomethylating agent-treated myelodysplastic neoplasms.
K. Chien, Ziyi Li, L. Lanino, N. Al Ali +31 more
2026Leukemia1 citations
Semantic Scholar
Results Of Third-Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia
Wei-Ying Jen, E. Jabbour, E. Kugler, Nitin Jain +8 more
2026Clinical Lymphoma, Myeloma & Leukemia1 citations Open access
Semantic Scholar
Results of second‐line therapy in adult Philadelphia chromosome‐positive acute lymphoblastic leukemia
H. Kantarjian, Wei-Ying Jen, E. Kugler, Rebecca E. Garris +8 more
2026Cancer1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Short×38
Invite
N. Short — researcher profile on SciRah
T. Kadia×37
Invite
T. Kadia — researcher profile on SciRah
C. Dinardo×23
Invite
C. Dinardo — researcher profile on SciRah
S. Loghavi×23
Invite
S. Loghavi — researcher profile on SciRah

×23

Invite

G. Issa — researcher profile on SciRah

G. Garcia-Manero×20

Invite

G. Garcia-Manero — researcher profile on SciRah

H. Kantarjian×20

Invite

H. Kantarjian — researcher profile on SciRah

H. Kantarjian×20

Invite

H. Kantarjian — researcher profile on SciRah

Naval G. Daver×18

Invite

Naval G. Daver — researcher profile on SciRah

N. Pemmaraju×17

Invite

N. Pemmaraju — researcher profile on SciRah

Invite

F. Haddad — researcher profile on SciRah

Wei-Ying Jen×15

Invite

Wei-Ying Jen — researcher profile on SciRah